BioCentury
ARTICLE | Top Story

Investors not IMPRESSed as NewLink trial continues

May 12, 2015 2:17 AM UTC

NewLink Genetics Corp. (NASDAQ:NLNK) lost $9.74 (19%) to $42.40 in after-hours trading on Monday after it said it would continue the Phase III IMPRESS trial of HyperAcute Pancreas algenpantucel-L to treat resected pancreatic cancer.

The company based its decision on a second interim analysis of IMPRESS data. Last March, the company said its first interim analysis did not support stopping the trial early (see BioCentury Extra, March 7, 2014). ...